## COVID-19 pandemic and admission rates for and management of acute coronary syndromes in Israel

E. Asher<sup>1</sup>, A. Fardman<sup>2</sup>, D. Zahger<sup>3</sup>, K. Orvin<sup>4</sup>, M. Mohsen<sup>5</sup>, O. Tsafrir<sup>6</sup>, R. Rubinshtein<sup>7</sup>, J. Jamal<sup>8</sup>, R. Efraim<sup>9</sup>, N. Kofman<sup>10</sup>, M. Halabi<sup>11</sup>, Y. Shacham<sup>12</sup>, L. Henri Fortis<sup>13</sup>, R. Beigel<sup>2</sup>, S. Matetzky<sup>2</sup>

<sup>1</sup> Shaare Zedek Medical Center, Jerusalem, Israel; <sup>2</sup> Sheba Medical Center, Heart Institute, Ramat Gan, Israel; <sup>3</sup> Soroka University Medical Center, Beer Sheva, Israel; <sup>4</sup> Rabin Medical Center, Petah Tikva, Israel; <sup>5</sup> Hillel Yaffe Medical Center, Hadera, Israel; <sup>6</sup> Western Galile Hospital, Nahariya, Israel; <sup>7</sup> The Edith Wolfson Medical Center, Holon, Israel; <sup>8</sup> Barzilai Medical Center, Ashkelon, Israel; <sup>9</sup> Rambam Health Care Campus, Haifa, Israel; <sup>10</sup> Meir Medical Center, Kfar Saba, Israel; <sup>11</sup> Ziv Medical Center, Safed, Israel; <sup>12</sup> Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; <sup>13</sup> Assuta Medical Center, Tel Aviv, Israel; <sup>14</sup> Assuta Medical Center, Tel Aviv, Israel

Funding Acknowledgement: Type of funding sources: None.

**Background:** Since the COVID-19 pandemic outbreak several countries have reported a decrease in the number of patients admitted with non-ST elevation myocardial infarction (NSTEMI).

**Purpose:** We aimed to evaluate admission trend and outcomes of patients with NSTEMI in the COVID-19 era in a nationwide survey.

**Methods:** A prospective, multicenter, observational, nationwide study involving 13 medical centers across Israel. All NSTEMI patients admitted to intensive cardiac care units (ICCUs) over an 8-week period during the COVID-19 outbreak were compare them with NSTEMI patients admitted 2 years earlier (control period) during the Acute Coronary Syndrome Israeli Survey (ACSIS) 2018.

Results: There were 624 (43%) NSTEMI patients, of them 349 (56%) hospitalized during the COVID-19 era and 275 (44%) during the control period, representing a 27% increase in NSTEMI admission rate during the COVID-19 era. Approximately 76% were male, median age was 67 years (IQR 58–76). There were no differences in baseline characteristics between the two

study periods. During the COVID-19 era, more patients arrived at the hospital via an emergency medical system (EMS) compared with the control period (p for trend = 0.005)

Time from symptom onset to hospital admission was longer in the COVID-19 era [687.00 (IQR147–2805) vs. 178.00 (IQR 102- 407), respectively, p-value <0.001]. Nevertheless, time from hospital admission to reperfusion was similar in both groups. Rate of percutaneous coronary intervention was higher in the COVID-19 era group (91.3% vs. 59.7%, respectively, p<0.001). In-hospital mortality rate was similar in both groups (2.3% vs. 4.7%, respectively, p=0.149) as was the 30-day mortality rate (3.7% vs. 5.1%, respectively, p=0.238).

**Conclusions:** In contrast to previous reports, in Israel, admission rate of NSTEMI was increased during the COVID-19 era. With longer time from symptoms to admission, but with the same time from hospital admission to reperfusion therapy and with similar in-hospital and 30-day mortality rates.